A study in The New England Journal of Medicine shows omalizumab increases allergen tolerance in individuals with multiple food allergies, offering a promising standalone treatment option.
FILAMENT HEALTH ENTERS LICENSING AGREEMENT WITH RESET PHARMA – Psychedelic Alpha
Reset Pharma has licensed Filament’s botanical psilocybin drug candidate for a phase 2 clinical trial studying demoralization syndrome VANCOUVER, BC, Aug. 31, 2023 /CNW/ –